Nanoligent
Nanoligent is a biotechnology spin-off that develops targeted drug therapies using a protein engineering platform to create nanoparticles. Their primary product under development is a protein conjugate that targets the CXCR4 receptor to deliver site-specific treatment for cancer and metastasis. The company focuses on the oncology market, aiming to provide systemic drug delivery with reduced adverse effects compared to traditional treatments.
Visit websiteCerdanyola del Vallès, Spain
Biotechnology
Oncology
Healthtech
Nanotechnology
Funding summary
- Total raised
- €13.0M
- Funding rounds
- 2
Investors in Nanoligent
Investors on record for Nanoligent. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Nanoligent?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors